News

Facts

18. March, 2024

Acute pain treatment – large unmet need, paediatrics receive least…mainly due to inadequate solutions

More than 20 million children annually, alone in Europe, are subject to acute pain...

Read more

Releases

29. February, 2024

Annual Report 2023

Cessatech A/S publishes its annual report for the fiscal year 2023, which also includes...

Read more

Facts

12. February, 2024

Treating children is not just like treating small adults

  Giving medicine to children can’t be a one-size-fits-all approach. Their changing anatomy and...

Read more

Releases

9. January, 2024

Cessatech 2024 major milestones and focus

Now is the time – 2024 will be an extremely busy and hopefully exciting...

Read more

Releases

4. January, 2024

Q&A session – topline data from Study 0205

Link to release: (Link to Q&A session-image)

Read more

Releases

22. December, 2023

Positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001

The study a double-blinded, randomised, placebo-controlled in adults demonstrated that CT001 was superior to...

Read more

Releases

21. September, 2023

Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001

Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of...

Read more

Releases

12. September, 2023

Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children

On 12 September – Cessatech A/S (“Cessatech” or “the Company”) announces that EMA’s Paediatric...

Read more

Releases

31. August, 2023

August business update

  A short update to the great progress we continue to make….thanks for reading!...

Read more

Facts

25. August, 2023

New findings supporting CT001

Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...

Read more

Releases

24. August, 2023

Second quarter report Q2-2023

US co-development and commercialization partnership signed for CT001 – potential income already from 2024...

Read more

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.